Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 NHLLRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTmZldKSzVyPUCuNFAxOjh5IN88US=> MX\TRW5ITVJ?
LC-2-ad Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\zTWM2OD1yLkCwNFMyPyEQvF2= NF3nOHdUSU6JRWK=
RL95-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMECwOlY5KM7:TR?= NHH5NZVUSU6JRWK=
MZ1-PC NETEdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMECwO|I6KM7:TR?= MmXyV2FPT0WU
TE-8 M3O3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzH[mtKSzVyPUCuNFAyOTdizszN Mm\lV2FPT0WU
SW954 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32ySmlEPTB;MD6wNFEyQSEQvF2= NIizeWRUSU6JRWK=
TE-11 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3njfGlEPTB;MD6wNFEzOyEQvF2= Mlv1V2FPT0WU
PSN1 NUPue2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1yLkCwNVMh|ryP NH7MT3FUSU6JRWK=
MOLT-4 NWHzdGt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiyTWM2OD1yLkCwNVQ6KM7:TR?= NVHTZocyW0GQR1XS
697 NGraSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqwV3pKSzVyPUCuNFAyPSEQvF2= MlX2V2FPT0WU
ETK-1 M4rxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV65OFhKUUN3ME2wMlAxOTV{IN88US=> MXfTRW5ITVJ?
TE-10 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfpTWM2OD1yLkCwNVU1KM7:TR?= NHTtOVFUSU6JRWK=
HUTU-80 M2TEZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTCTWM2OD1yLkCwNVY5KM7:TR?= MlLvV2FPT0WU
NTERA-S-cl-D1 M3XLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL4eJY2UUN3ME2wMlAxOjB7IN88US=> MmPwV2FPT0WU
MFH-ino NFXBXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XuU2lEPTB;MD6wNFI3QCEQvF2= MXPTRW5ITVJ?
IA-LM Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrjTlA1UUN3ME2wMlAxOjhizszN MorWV2FPT0WU
MC116 M2XDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjwTWM2OD1yLkCwNlg6KM7:TR?= MV3TRW5ITVJ?
RKO M1LvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMECyPVgh|ryP MmTiV2FPT0WU
MRK-nu-1 M2ftc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\DZ2lEPTB;MD6wNFI6QSEQvF2= MVzTRW5ITVJ?
VA-ES-BJ MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG5cHdKSzVyPUCuNFA{KM7:TR?= MUjTRW5ITVJ?
KALS-1 MoSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSwR5A5UUN3ME2wMlAxOzB6IN88US=> NH\wWIVUSU6JRWK=
BB30-HNC Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Cwc2lEPTB;MD6wNFMyPCEQvF2= MUPTRW5ITVJ?
ACN NEDrW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPWTWM2OD1yLkCwN|E3KM7:TR?= NXTPTYNwW0GQR1XS
TE-9 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:3TWM2OD1yLkCwN|I3KM7:TR?= MkTYV2FPT0WU
SIG-M5 NXrxd5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPPVYZ5UUN3ME2wMlAxOzJ5IN88US=> MYDTRW5ITVJ?
no-10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMECzOlIh|ryP NFfRN5dUSU6JRWK=
EW-1 NVO4WnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfsWGJKSzVyPUCuNFA{PzFizszN NH7WdnpUSU6JRWK=
SK-LMS-1 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfOc21KSzVyPUCuNFA1ODFizszN MmPDV2FPT0WU
GT3TKB NWLiO5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j3[WlEPTB;MD6wNFQ{PCEQvF2= NGPvb3BUSU6JRWK=
ES4 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEC0OFkh|ryP M{T4PHNCVkeHUh?=
IMR-5 M2rxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLWW5ZwUUN3ME2wMlAxPDVizszN NILvVlFUSU6JRWK=
NCI-H1648 NGLxfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X4bWlEPTB;MD6wNFQ3QSEQvF2= NVv5Z3JrW0GQR1XS
MV-4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzD[oZJUUN3ME2wMlAxPDd3IN88US=> NULCWY8zW0GQR1XS
SK-UT-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTZUIU2UUN3ME2wMlAxPDhizszN NHjY[lZUSU6JRWK=
NB13 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEC0PVEh|ryP M1fkUXNCVkeHUh?=
DJM-1 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jwNGlEPTB;MD6wNFU{KM7:TR?= MUXTRW5ITVJ?
ES8 NF7FWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5cWNMUUN3ME2wMlAxPTN6IN88US=> MV7TRW5ITVJ?
TE-6 NH\hNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT2V4h1UUN3ME2wMlAxPTdizszN NYTjZ2MxW0GQR1XS
KS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3mU41PUUN3ME2wMlAxPTh{IN88US=> NHnufGlUSU6JRWK=
TE-1 M136e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WwNWlEPTB;MD6wNFYxPiEQvF2= MXLTRW5ITVJ?
ATN-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXxTWM2OD1yLkCwOlA6KM7:TR?= NES5folUSU6JRWK=
A4-Fuk Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvLTWM2OD1yLkCwOlEyKM7:TR?= MkTRV2FPT0WU
ALL-PO M2DrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[zfmlEPTB;MD6wNFY{KM7:TR?= MmThV2FPT0WU
BE-13 NGrBVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;0U4JKSzVyPUCuNFA3OzZizszN M4\5Z3NCVkeHUh?=
KM12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7lV4xqUUN3ME2wMlAxPjN5IN88US=> Mn20V2FPT0WU
NOS-1 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\aTWM2OD1yLkCwOlUh|ryP M3Xjc3NCVkeHUh?=
SW962 NYexS4RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC2OlIh|ryP NYfBVm5PW0GQR1XS
OCUB-M MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnVVohjUUN3ME2wMlAxPjZ{IN88US=> Mn\UV2FPT0WU
NCI-H510A M4DadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKye5ZuUUN3ME2wMlAxPjZ3IN88US=> NUfSS2I3W0GQR1XS
EW-16 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;VPGlEPTB;MD6wNFY6PCEQvF2= NWfVdoM{W0GQR1XS
KGN MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMEC3NVIh|ryP Ml;CV2FPT0WU
LS-411N NHvicmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEC3NVch|ryP NWPsVW1bW0GQR1XS
Becker M4Lld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nEVmlEPTB;MD6wNFczKM7:TR?= M1;wNXNCVkeHUh?=
HC-1 M{HrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMOmlEPTB;MD6wNFczOSEQvF2= M360cnNCVkeHUh?=
CESS MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfocFZKSzVyPUCuNFA4OzdizszN NUPDUm91W0GQR1XS
KURAMOCHI NXW3OFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XzfmlEPTB;MD6wNFc1QCEQvF2= NHO4RXZUSU6JRWK=
TGBC24TKB NWD1UHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMEC3OVIh|ryP NXTNVo82W0GQR1XS
SW982 NEHOVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHSXlJEUUN3ME2wMlAxPzZ4IN88US=> NYLhVpFWW0GQR1XS
HCE-4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfBW3RTUUN3ME2wMlAxPzZ5IN88US=> NIL4SlVUSU6JRWK=
LOUCY MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL4TWM2OD1yLkCwO|c2KM7:TR?= MlfTV2FPT0WU
8-MG-BA M2XMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT3TWM2OD1yLkCwO|k3KM7:TR?= MX7TRW5ITVJ?
HT-144 M1rTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vtT2lEPTB;MD6wNFgh|ryP Mk[zV2FPT0WU
LXF-289 NVLpfYtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEC4NVgh|ryP MlP4V2FPT0WU
RS4-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljJTWM2OD1yLkCwPFM3KM7:TR?= MX;TRW5ITVJ?
DEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLvTWM2OD1yLkCwPFQ2KM7:TR?= M4LhW3NCVkeHUh?=
OCI-AML2 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTX[mZkUUN3ME2wMlAxQDV{IN88US=> NXvSb|Y1W0GQR1XS
CCRF-CEM NWPPVndtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEC4O|Eh|ryP NWizb3ZoW0GQR1XS
A388 M3;qW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5TVluUUN3ME2wMlAxQDd2IN88US=> NWrjNGJsW0GQR1XS
KNS-42 M2XWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G1dmlEPTB;MD6wNFg6OSEQvF2= NILTUFBUSU6JRWK=
OVCAR-4 M17TO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFX1dlZKSzVyPUCuNFA6ODRizszN MmTYV2FPT0WU
NCI-H1355 NU\hRZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrUUYNTUUN3ME2wMlAxQTF2IN88US=> NV3DSJF4W0GQR1XS
BL-70 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEC5N{DPxE1? NEDXOYpUSU6JRWK=
BL-41 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLhTWM2OD1yLkCwPVM1KM7:TR?= NFTTXmlUSU6JRWK=
A101D NEnXblFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXB[3FuUUN3ME2wMlAxQTZizszN NW\kdIx[W0GQR1XS
HL-60 M2TCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTD[IFmUUN3ME2wMlAxQTZ4IN88US=> NVToOWF3W0GQR1XS
COR-L279 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMEC5PVkh|ryP M1LMbXNCVkeHUh?=
NCI-SNU-16 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLQTWM2OD1yLkCxNFA5KM7:TR?= NUPDTIl1W0GQR1XS
Calu-6 NXnkeWZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq4TWM2OD1yLkCxNFEzKM7:TR?= MVjTRW5ITVJ?
SR NV;qXXEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXnPVJ3UUN3ME2wMlAyODJ4IN88US=> MmjFV2FPT0WU
QIMR-WIL MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\YS2lEPTB;MD6wNVA{OyEQvF2= NILt[4xUSU6JRWK=
LB647-SCLC NYHrbYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMEGwOVEh|ryP NVHHXlhsW0GQR1XS
RPMI-8226 NX:0[4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKxTWM2OD1yLkCxNVAzKM7:TR?= M3i5fXNCVkeHUh?=
SK-PN-DW Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn0TWM2OD1yLkCxNVEzKM7:TR?= NXf2N4ZrW0GQR1XS
SF268 NILGXpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr6eVBKSzVyPUCuNFEyPTFizszN NITncXhUSU6JRWK=
HD-MY-Z NVjWeY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL5W3JKSzVyPUCuNFEyPjNizszN NIXKV2FUSU6JRWK=
DOHH-2 M3\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzHTWM2OD1yLkCxNlA{KM7:TR?= MVvTRW5ITVJ?
SCC-3 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTBwMEGyNFQh|ryP NUixU3ZJW0GQR1XS
ST486 NFzacZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r6R2lEPTB;MD6wNVIxPCEQvF2= NEfjTXNUSU6JRWK=
NALM-6 M2fPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;1WGtKSzVyPUCuNFEzOTRizszN M3zpTnNCVkeHUh?=
NCI-H1436 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XNSmlEPTB;MD6wNVI{OSEQvF2= MkDpV2FPT0WU
KE-37 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PDe2lEPTB;MD6wNVI{PCEQvF2= M{K0SHNCVkeHUh?=
RPMI-8402 NVLQOHR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHiVoI1UUN3ME2wMlAyOjV4IN88US=> NHvaPXlUSU6JRWK=
RXF393 M3fDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEGyOVch|ryP NGDzW4VUSU6JRWK=
KARPAS-45 NVT5[Il1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMEGyO{DPxE1? NH7obXRUSU6JRWK=
HOP-62 NXzkZWpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jOW2lEPTB;MD6wNVI4PiEQvF2= NFzhSoRUSU6JRWK=
ES1 NVvvZmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLUdmQxUUN3ME2wMlAyOjh6IN88US=> M3OzNnNCVkeHUh?=
L-363 MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zaOWlEPTB;MD6wNVM2OSEQvF2= NUfjR5l5W0GQR1XS
GI-1 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLNTWM2OD1yLkCxN|c{KM7:TR?= NXTzNotnW0GQR1XS
CTV-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fmZ2lEPTB;MD6wNVQ4QCEQvF2= NVTNfllwW0GQR1XS
TE-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMEG0PVYh|ryP NUXGWI04W0GQR1XS
SNU-C2B NVSzRXFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMEG0PVYh|ryP NXzzdIpIW0GQR1XS
K-562 M2PCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTWTWM2OD1yLkCxOVE3KM7:TR?= M4\FR3NCVkeHUh?=
SNB75 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXyTWM2OD1yLkCxOVQh|ryP MVjTRW5ITVJ?
MOLT-13 M1zLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne0TWM2OD1yLkCxOlM4KM7:TR?= M3LlbHNCVkeHUh?=
LS-123 NG\6UllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;PemZKSzVyPUCuNFE3PjRizszN MUDTRW5ITVJ?
NCI-SNU-5 NELRXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm5e3dKSzVyPUCuNFE4ODFizszN M4G3NXNCVkeHUh?=
Daudi MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEG3NFgh|ryP NGTo[nlUSU6JRWK=
A253 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTGbVhDUUN3ME2wMlAyPzN6IN88US=> NGm0dYtUSU6JRWK=
TGBC1TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLqTWM2OD1yLkCxO|UzKM7:TR?= MoXDV2FPT0WU
SJSA-1 NHzIb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;keGJXUUN3ME2wMlAyPzZ5IN88US=> MYnTRW5ITVJ?
NCCIT MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD5eXJKSzVyPUCuNFE4PjlizszN MXjTRW5ITVJ?
NCI-H69 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEG3O|gh|ryP M2W5c3NCVkeHUh?=
SH-4 NH7UTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXIO292UUN3ME2wMlAyQDl3IN88US=> M4mzSnNCVkeHUh?=
HCC1187 NHjFUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HJUWlEPTB;MD6wNVkzPCEQvF2= NHPFSHFUSU6JRWK=
HCC1599 NGLDWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33wbWlEPTB;MD6wNlAzKM7:TR?= NGDZSHRUSU6JRWK=
ONS-76 NWjZdYx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMEKwN|Yh|ryP NWDnT3JzW0GQR1XS
KU812 M4jGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3GzZmlEPTB;MD6wNlA{QSEQvF2= MVXTRW5ITVJ?
ML-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nFTGlEPTB;MD6wNlA1PyEQvF2= MULTRW5ITVJ?
HCE-T MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPvVpFKSzVyPUCuNFIxQTJizszN NFr5b3FUSU6JRWK=
NCI-H446 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEKxNVIh|ryP NVu1ZXVLW0GQR1XS
RPMI-6666 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HXfGlEPTB;MD6wNlE1QSEQvF2= MkW1V2FPT0WU
MOLT-16 NYXnTmpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfkdFFKSzVyPUCuNFIyPTNizszN NWrjUGJGW0GQR1XS
JiyoyeP-2003 MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEKxO|Yh|ryP M1;h[XNCVkeHUh?=
MHH-PREB-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3znd2lEPTB;MD6wNlE6OSEQvF2= Ml7LV2FPT0WU
MC-CAR MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEKzNlYh|ryP MmnPV2FPT0WU
BC-3 NX;jPIZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMEKzOFQh|ryP NVrDWFlXW0GQR1XS
KINGS-1 M{\tO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\0TWM2OD1yLkCyN|U2KM7:TR?= M3jyenNCVkeHUh?=
PF-382 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTKNpl7UUN3ME2wMlAzOzd6IN88US=> M3LT[3NCVkeHUh?=
J-RT3-T3-5 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn1TWM2OD1yLkCyN|g{KM7:TR?= MVjTRW5ITVJ?
SF539 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEK0NFEh|ryP MmrIV2FPT0WU
LB831-BLC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEK0PFUh|ryP MlnqV2FPT0WU
DMS-114 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEK1NFIh|ryP M3rDdXNCVkeHUh?=
LB1047-RCC NIrZOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1yLkCyOVEh|ryP M1u0cXNCVkeHUh?=
LB771-HNC NYPT[WdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOxem9sUUN3ME2wMlAzPTN2IN88US=> MnjOV2FPT0WU
BB65-RCC M3vKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHXdo5KSzVyPUCuNFI2OzRizszN M3fuN3NCVkeHUh?=
BV-173 NW\DZ4JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfETWM2OD1yLkCyOVU1KM7:TR?= MXHTRW5ITVJ?
ARH-77 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0[GlEPTB;MD6wNlYxOSEQvF2= NXfpPWg1W0GQR1XS
IST-MEL1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHBTWM2OD1yLkCyOlI{KM7:TR?= MnzKV2FPT0WU
NB1 NIXTTIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEK2PFch|ryP NFXySVhUSU6JRWK=
EoL-1-cell NHqyUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\POWtKSzVyPUCuNFI3QDhizszN NEe3VHhUSU6JRWK=
KY821 NHizeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEK2PVch|ryP MYLTRW5ITVJ?
CMK MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf6ZWdiUUN3ME2wMlAzPzN2IN88US=> M4LmfHNCVkeHUh?=
NCI-H2126 M3XmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe5bHg4UUN3ME2wMlAzPzZ6IN88US=> NXW3XpBnW0GQR1XS
NCI-H526 M3LCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMEK4PVEh|ryP M3v2WXNCVkeHUh?=
COLO-684 NETIbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfTO2tmUUN3ME2wMlAzQTB6IN88US=> MknVV2FPT0WU
NCI-H747 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVeI97UUN3ME2wMlAzQTN|IN88US=> MUDTRW5ITVJ?
JAR MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXPTWM2OD1yLkCyPVQ3KM7:TR?= MYXTRW5ITVJ?
MEG-01 M3rKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX0OVJnUUN3ME2wMlAzQTd6IN88US=> NHrXTYpUSU6JRWK=
MONO-MAC-6 M2fVTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fScmlEPTB;MD6wN|AzOyEQvF2= MXTTRW5ITVJ?
IST-SL1 NWDaOoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknDTWM2OD1yLkCzNFQzKM7:TR?= MnexV2FPT0WU
CPC-N Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BVIFKSzVyPUCuNFMxPzlizszN MYPTRW5ITVJ?
NCI-H1963 NXric2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfGTWM2OD1yLkCzNVMyKM7:TR?= MUDTRW5ITVJ?
K052 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnFTWs3UUN3ME2wMlA{OjR5IN88US=> NVXVNpJXW0GQR1XS
KM-H2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEOzNFch|ryP MnLWV2FPT0WU
TE-12 NWjrXo41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrne5RCUUN3ME2wMlA{OzB7IN88US=> NXjGU2hPW0GQR1XS
TK10 NFK5O4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrQTWM2OD1yLkCzN|U3KM7:TR?= NU\QT|F{W0GQR1XS
NMC-G1 NHvVR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\qVFFKSzVyPUCuNFM1PTJizszN M3jl[3NCVkeHUh?=
no-11 NEHDNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfuTppKSzVyPUCuNFM1PzhizszN NHTWRolUSU6JRWK=
NCI-H524 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrkR49KSzVyPUCuNFM2OjlizszN NXnRc|FUW0GQR1XS
MHH-CALL-2 NUnaPHhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPSVoxYUUN3ME2wMlA{PTZ{IN88US=> NWTLeGxtW0GQR1XS
GB-1 NYPwV|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEO2JO69VQ>? Mnu4V2FPT0WU
OPM-2 M4rkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEO2O|Mh|ryP NWDlXVY2W0GQR1XS
RH-1 NGjTNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln6TWM2OD1yLkCzPFE6KM7:TR?= MlvQV2FPT0WU
NCI-H64 NULRR2pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjvSW1CUUN3ME2wMlA{QDV5IN88US=> Mnj5V2FPT0WU
EVSA-T NHzSZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTsTWM2OD1yLkCzPVI{KM7:TR?= M4HZdXNCVkeHUh?=
KARPAS-299 NGDwU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfqSotKSzVyPUCuNFM6QCEQvF2= NH;ERZZUSU6JRWK=
MZ7-mel MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160TGlEPTB;MD6wOFA1KM7:TR?= MkfPV2FPT0WU
LB373-MEL-D NG\5XVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMESxNFUh|ryP M3Sxb3NCVkeHUh?=
HEL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\jZ2lEPTB;MD6wOFE1KM7:TR?= MYXTRW5ITVJ?
SW872 M2PpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rTV2lEPTB;MD6wOFIyKM7:TR?= NET6WHBUSU6JRWK=
DU-4475 NWnre2FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\jdFZWUUN3ME2wMlA1OjR2IN88US=> MofMV2FPT0WU
IST-SL2 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMESyO|Uh|ryP NUHGR5hYW0GQR1XS
NCI-H82 NYnTbHZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULvelJ{UUN3ME2wMlA1OzB5IN88US=> NXzld2YxW0GQR1XS
LC4-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nMUWlEPTB;MD6wOFM2OSEQvF2= M17kW3NCVkeHUh?=
HDLM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPUT3pZUUN3ME2wMlA1Ozl{IN88US=> NInWd21USU6JRWK=
MMAC-SF NY\rO|VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW2TWlGUUN3ME2wMlA1PTN2IN88US=> MWXTRW5ITVJ?
L-540 NInBNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2KzOGlEPTB;MD6wOFY{QSEQvF2= NE\vdVFUSU6JRWK=
MZ2-MEL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXiW4xEUUN3ME2wMlA1PzR{IN88US=> MnzDV2FPT0WU
LU-134-A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMES3O|Mh|ryP NYPvUJdnW0GQR1XS
UACC-257 M{LR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zrc2lEPTB;MD6wOFg1QSEQvF2= Mn;zV2FPT0WU
NCI-H1581 NFX1PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7TcnpKSzVyPUCuNFQ6PTNizszN NVPuSJR3W0GQR1XS
NB17 M3;YVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYK0U40xUUN3ME2wMlA1QTd7IN88US=> NYmzeo92W0GQR1XS
SBC-1 M1n0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzt[2xuUUN3ME2wMlA2ODR{IN88US=> MVnTRW5ITVJ?
TALL-1 NVjhWZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjhVWk3UUN3ME2wMlA2ODR3IN88US=> MVHTRW5ITVJ?
NCI-H1304 NGXTUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\KTWM2OD1yLkC1NlA5KM7:TR?= NXOwTGt{W0GQR1XS
NEC8 NID4WmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTTWM2OD1yLkC1Nlg3KM7:TR?= NGXOTm5USU6JRWK=
CAL-148 NV7BUopnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17sV2lEPTB;MD6wOVQ{QSEQvF2= NHTkTnhUSU6JRWK=
CGTH-W-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1ZpRKSzVyPUCuNFU1PDlizszN MV\TRW5ITVJ?
NCI-H889 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXe0U4FyUUN3ME2wMlA2PTl{IN88US=> NGH0Z2xUSU6JRWK=
GR-ST NV\rWHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnaRoxKSzVyPUCuNFU3OjFizszN MnvkV2FPT0WU
KARPAS-422 NIK1OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwMEW2OUDPxE1? MUjTRW5ITVJ?
RPMI-8866 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7QVFRKSzVyPUCuNFU4OTJizszN MkjBV2FPT0WU
SCLC-21H M1S1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\XfGJSUUN3ME2wMlA2QDh2IN88US=> NYL1XGI4W0GQR1XS
COR-L88 NFXDXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEW5Nlch|ryP NHfqeZlUSU6JRWK=
LU-139 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEW5PFYh|ryP M3zBRXNCVkeHUh?=
SF126 M1PDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjzcnFKSzVyPUCuNFYyOzNizszN Mn7UV2FPT0WU
NCI-H1882 NXS1VnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTJR2FKSzVyPUCuNFY1OjRizszN NX;OZ5pLW0GQR1XS
EW-24 M3\SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYny[WFkUUN3ME2wMlA3PDh|IN88US=> MXfTRW5ITVJ?
CP67-MEL NF3mdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3yTWM2OD1yLkC2PFEh|ryP M3rzeXNCVkeHUh?=
DG-75 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7WemRTUUN3ME2wMlA3QDl7IN88US=> MlvYV2FPT0WU
LOXIMVI NEO1WXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKz[|VKSzVyPUCuNFcxOjhizszN MV3TRW5ITVJ?
HH NGH3XYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pUWJKSzVyPUCuNFcyPTdizszN MYXTRW5ITVJ?
K5 NUnj[FNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknTTWM2OD1yLkC3NlI3KM7:TR?= M2LWe3NCVkeHUh?=
EC-GI-10 NEDaO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTpeY5FUUN3ME2wMlA4OjV5IN88US=> M{LMXnNCVkeHUh?=
SK-N-DZ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjXTXUxUUN3ME2wMlA4OzB5IN88US=> NES2WopUSU6JRWK=
A3-KAW MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEezOVEh|ryP M1H4UHNCVkeHUh?=
MLMA NW\SV3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\RdmlEPTB;MD6wO|Q3PSEQvF2= M3W2U3NCVkeHUh?=
LB996-RCC MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jZTGlEPTB;MD6wO|cxPyEQvF2= M{[yfnNCVkeHUh?=
OS-RC-2 NGfJeVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnKfVM5UUN3ME2wMlA4PzR6IN88US=> NVrqXnZZW0GQR1XS
CTB-1 M1rsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOVYRCUUN3ME2wMlA4QDFizszN NFn0dZhUSU6JRWK=
IST-MES1 NX7IWWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3uye2lEPTB;MD6wO|kyOiEQvF2= NVfSU2Q{W0GQR1XS
LS-1034 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXITWM2OD1yLkC4NFM2KM7:TR?= NX:1UGVLW0GQR1XS
HT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEiwPFYh|ryP MX3TRW5ITVJ?
NCI-H2141 NGPCVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsUGlEPTB;MD6wPFEh|ryP MmjRV2FPT0WU
LB2518-MEL NUfwOoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEixOFEh|ryP Mmr4V2FPT0WU
GI-ME-N MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zwOmlEPTB;MD6wPFQ2OiEQvF2= Ml\FV2FPT0WU
TGW MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHTWM2OD1yLkC4OlA4KM7:TR?= MYHTRW5ITVJ?
SK-NEP-1 MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vyeGlEPTB;MD6wPFY1OSEQvF2= MUjTRW5ITVJ?
NOMO-1 NV7UZ5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LvcmlEPTB;MD6wPVI4PSEQvF2= M333PHNCVkeHUh?=
ES6 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknDTWM2OD1yLkC5OVg6KM7:TR?= NUjKT2JrW0GQR1XS
NCI-H209 NH3PW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEm3PFYh|ryP NHv4c3pUSU6JRWK=
GAK NV;TVHB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMUCxOkDPxE1? MVvTRW5ITVJ?
BC-1 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMUCzOlEh|ryP NFTtVodUSU6JRWK=
KLE MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMUC0OFMh|ryP Ml3lV2FPT0WU
EW-3 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;NS5NtUUN3ME2wMlExQThizszN NYLRU|VjW0GQR1XS
NKM-1 Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMUGxJO69VQ>? MlzoV2FPT0WU
D-336MG M{PYdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH2TWM2OD1yLkGxNlQ1KM7:TR?= NWX4UGlHW0GQR1XS
NB69 NFTOXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGizNVRKSzVyPUCuNVE{ODFizszN NELoVI1USU6JRWK=
D-263MG NHXMWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMUG3NVIh|ryP MmXaV2FPT0WU
KP-N-YS MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnTWM2OD1yLkGyNlkyKM7:TR?= MoC3V2FPT0WU
NCI-H1155 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn0TZliUUN3ME2wMlEzPTV6IN88US=> MWTTRW5ITVJ?
BOKU NHTL[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GwO2lEPTB;MD6xNlU4QSEQvF2= MWPTRW5ITVJ?
LAMA-84 NYK5dJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDRTWM2OD1yLkGyPVkh|ryP M{S2dHNCVkeHUh?=
Raji NVzjUoM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mySGlEPTB;MD6xN|EyPyEQvF2= MX;TRW5ITVJ?
LU-65 NXjjO216T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT0PFdiUUN3ME2wMlE{OzB5IN88US=> NEL0OJRUSU6JRWK=
NCI-H187 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvufXJZUUN3ME2wMlE{QTJ2IN88US=> MlfUV2FPT0WU
GCIY NG\qVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fsR2lEPTB;MD6xOFkxOSEQvF2= NWXwXmVyW0GQR1XS
NCI-H2107 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtNpZKSzVyPUCuNVUxQCEQvF2= M2nlOHNCVkeHUh?=
NCI-H1522 NITPNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moe3TWM2OD1yLkG1NlY3KM7:TR?= MlmxV2FPT0WU
NB6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KUohKUUN3ME2wMlE2PjJ|IN88US=> M4H5XnNCVkeHUh?=
EM-2 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXpe2hKSzVyPUCuNVU4ODZizszN M2e0d3NCVkeHUh?=
HCC2218 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX22OG4{UUN3ME2wMlE2QThizszN NGiyNmZUSU6JRWK=
NCI-H748 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi4TWM2OD1yLkG2N|c3KM7:TR?= Mne4V2FPT0WU
MS-1 NInN[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvPIVCUUN3ME2wMlE3PTN5IN88US=> MXvTRW5ITVJ?
NB5 M1TUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\lTWM2OD1yLkG2OVk4KM7:TR?= MoXPV2FPT0WU
OMC-1 NWqxRXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMU[2PFgh|ryP MVrTRW5ITVJ?
NCI-H345 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSyTWM2OD1yLkG2PVI5KM7:TR?= NWXHVIl6W0GQR1XS
L-428 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3LbodKSzVyPUCuNVY6PDVizszN MoD3V2FPT0WU
SCH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH5c3lIUUN3ME2wMlE5Pjh3IN88US=> M4HINXNCVkeHUh?=
NCI-H1417 NGC5O3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13jfGlEPTB;MD6xPVIzPyEQvF2= NXXZfHhMW0GQR1XS
COLO-320-HSR NV;kdGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMUm1N|Ih|ryP NVq0NlVYW0GQR1XS
BT-474 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDq[W1jUUN3ME2wMlIxQDl{IN88US=> MlLpV2FPT0WU
GDM-1 NV\rVVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fzUGlEPTB;MD6yNVk4OSEQvF2= MU\TRW5ITVJ?
NCI-H2196 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;EPHNKSzVyPUCuNlIzOzVizszN MV7TRW5ITVJ?
KP-N-RT-BM-1 NVW5e5dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq0cWRCUUN3ME2wMlIzOzR7IN88US=> NWDhZWVUW0GQR1XS
KNS-81-FD MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK5d2FvUUN3ME2wMlIzQTV6IN88US=> MYTTRW5ITVJ?
COLO-668 M3LSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnntTWM2OD1yLkKzOlc2KM7:TR?= NX;ob41jW0GQR1XS
C2BBe1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XPVWlEPTB;MD6yOlc1PyEQvF2= M3vSfXNCVkeHUh?=
Ramos-2G6-4C10 NHjhbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\yUWlEPTB;MD6yOlk2PCEQvF2= NVzLTpUxW0GQR1XS
CAS-1 NYPHR5ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDXTWM2OD1yLkK3NFk3KM7:TR?= NFjQdVNUSU6JRWK=
GOTO NGnRRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnUVm5KSzVyPUCuNlc5QTRizszN MkSyV2FPT0WU
LP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvMTFZFUUN3ME2wMlI5ODV5IN88US=> M{n0ZnNCVkeHUh?=
NCI-SNU-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\EWHRnUUN3ME2wMlI6PDJ{IN88US=> MV7TRW5ITVJ?
EB-3 NXTVZoo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMkm5O|kh|ryP MUTTRW5ITVJ?
MHH-NB-11 NVzuUG9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwM{C0NFIh|ryP MnKyV2FPT0WU
SK-N-FI M{LaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwM{G2PVIh|ryP NUfUTGN2W0GQR1XS
HCC2157 M4fJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXSe3NGUUN3ME2wMlM{QTF|IN88US=> MWPTRW5ITVJ?
SIMA MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwM{S1PFEh|ryP MnHJV2FPT0WU
MDA-MB-134-VI NFH5SnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPhTWM2OD1yLkO2PVI5KM7:TR?= NWWyNopiW0GQR1XS
NCI-H1694 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwM{eg{txO MnjsV2FPT0WU
EHEB NUf6VI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjqTWM2OD1yLkO5NFg2KM7:TR?= M{HSTnNCVkeHUh?=
U-266 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7zTWM2OD1yLkO5PFQ3KM7:TR?= MnntV2FPT0WU
LC-1F NGD6UppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXzNVBjUUN3ME2wMlQ{PzZ3IN88US=> MkjwV2FPT0WU
SHP-77 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLLTWM2OD1yLkS3PFU2KM7:TR?= MlzqV2FPT0WU
LS-513 NGr5TYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELBNZVKSzVyPUCuOFk{ODdizszN NELyUnFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02181634 Active, not recruiting Cholangiocarcinoma PrECOG, LLC.|Celgene Corporation December 9, 2014 Phase 2
NCT03047265 Active, not recruiting Nasopharyngeal Carcinoma Sun Yat-sen University February 4, 2017 Phase 2
NCT02779855 Not yet recruiting Breast Cancer|Ductal Carcinoma|Invasive Breast Carcinoma|Invasive Ductal Breast Carcinoma H. Lee Moffitt Cancer Center and Research Institute|Amgen April 30, 2017 Phase 1|Phase 2
NCT00001426 Completed Ovarian Neoplasm National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 1995 Phase 2
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT01051934 Completed Non-Small Cell Lung Cancer|Adenocarcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 29, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID